Click here to read the complete December 2018 Digital Edition.
Best Places to Work
MM&M unveils the results of its first-ever compilation of Best Places to Work in the healthcare agency world. We identify top destinations in each of three categories – small, medium, and large agencies – and identify just what it is that makes each of the honorees stand out among the competition. PLUS: Commentary from the judges’ panel on the attributes that impressed them most.
With 2019 just ahead, MM&M presents its annual assembly of previews and educated predictions for the new year. Our three-pronged approach includes in-depth looks at information and expected trends in and around healthcare policy, the pharma pipeline, and health-tech.
Improbably, pharma has found itself out of the government’s crosshairs during the first two years of the Trump administration (other than being on the receiving end of a few bombastic tweets, that is). How long will it last? We take a deep dive on the policy issues likely to affect marketers in the months ahead, including the recent proposal to require disclosure of drug pricing in DTC ads and related regulatory issues likely to play out during 2019.
We dive deep on the biopharma pipeline, examining potential breakthrough drug candidates in a wide range of therapeutic areas – everywhere from mainstays like neurology and respiratory to fast-evolving personal cancer therapies and orphans. The feature will also include exclusive lists of late-stage compounds and bulleted entries on the most buzzworthy prospects, alongside analyst commentary, recent clinical trial data, and financial forecasts.
MM&M sits down with several of the digital health companies and startups that generated the most VC investment and interest during 2018, pressing them on their plans for partnership with traditional pharma players as well as their new-era marketing tactics.
Agencies: Zero Tolerance?
Earlier this year, McCann Health fired its global chief creative officer following what it described as a complaint about a violation of the network’s code of conduct. It was the first high-profile sign that the #MeToo and #Time’s Up movements had caught up with the healthcare marketing sector. But are zero-tolerance policies and demonstrably swift action against cases of bad behavior a universal experience across the industry? Are agencies starting to take such charges seriously and not just sweep them under the rug, as has been typical in the past? We assess the impact of McCann’s move on the rest of the sector.